Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
"Encore Capital Group" Q2 2026 Earnings Call - Raised 2026 EPS and Collections Guidance Amid Record U.S. Debt Purchases and Refinancing Win
Encore Capital Group does not chase market trends. It exploits them. The second quarter of 2026 proved exactly that. U.S. consumer charge-offs sit at a decade high while revolving credit remains eleva...
- Global collections reached a record $737 million, up 13% year-over-year, driven by U.S. operational improvements and larger portfolio volumes.
- U.S. portfolio purchases totaled $372 million, contributing to a record $444 million in global acquisitions, with management highlighting increased success in the spot market.
- Full-year 2026 earnings per share guidance was raised to $13.00-$14.00, reflecting operational leverage and lower borrowing costs despite a $1.00 per share refinancing charge.
- +8 more takeaways
Cirrus Logic Q1 FY2027 Earnings Call - Record Revenue Driven by Strongest Mixed-Signal Pipeline in Company History
Cirrus Logic delivered a record first quarter, but the numbers tell a story of strategic pivoting rather than blind optimism. Revenue hit $460 million and non-GAAP earnings reached $1.84, buoyed by su...
- Record Q1 revenue of $460 million and non-GAAP EPS of $1.84 set a new high, driven by stronger smartphone component sales partially offset by anticipated pricing reductions.
- The high-performance mixed-signal pipeline for camera, battery, and power applications is described as the strongest in company history, with new smart power ICs for 3D sensing advancing on schedule.
- PC market expectations for fiscal 2027 were trimmed due to platform supply constraints, memory shortages, and OEM delays, though management frames this as a timing issue rather than a structural decline.
- +7 more takeaways
Talen Energy Q2 2026 Earnings Call - PJM Market Tightness and Cornerstone Acquisition Fuel Record Cash Flows and Aggressive Buyback Plan
Talen Energy is navigating a structurally tighter PJM market with a fleet that is running harder and pricing harder. The June close of the Cornerstone Acquisition added 2.5 gigawatts of efficient natu...
- Q2 adjusted EBITDA hit $374 million and adjusted free cash flow reached $212 million. Year-to-date free cash flow conversion is holding in the mid-60s percent range, with $1.9 billion in liquidity backing the balance sheet.
- The June close of the Cornerstone Acquisition added 2.5 gigawatts of efficient natural gas generation. Those assets are already contributing to elevated runtimes and higher realized market prices across the fleet.
- Management raised 2026 adjusted EBITDA guidance to $2.025 billion to $2.225 billion and pushed 2026 adjusted free cash flow up to $1.2 billion to $1.35 billion. Forward per-share free cash flow outlooks for 2027 and 2028 are climbing.
- +7 more takeaways
AbCellera Q2 2026 Earnings Call - TCE Platform Deals Inject $110M Upfront Cash and Validate Multi-Specific Pipeline
AbCellera is shedding its cash-burning discovery label and stepping into a de-risked clinical-stage operator. Enrollment for ABCL635 in menopausal hot flashes wrapped early, and management is tracking...
- ABCL635 Phase II enrollment for moderate to severe menopausal hot flashes finished ahead of schedule, with top-line data expected imminently.
- Management targets a 20 percent placebo-adjusted reduction in hot flash frequency and a minimum of two daily hot flash reductions as clinical success thresholds.
- ABCL635 aims to differentiate from approved small molecules by eliminating routine liver monitoring and avoiding NK1R-mediated somnolence through strict NK3R targeting.
- +9 more takeaways
Universal Technical Institute Q3 FY2026 Earnings Call - Guidance Trimmed on High School Conversion Miss, Skilled Trades Momentum and Long-Term Targets Hold
UTI delivered a clean third quarter with revenue climbing 7% to $219 million and new student starts surging 11%, yet management lowered full-year guidance to reflect a Q4 high school enrollment shortf...
- Third-quarter revenue rose 7% to $219 million, with new student starts jumping 11% year-over-year, driven by a 23% surge in the UTI division.
- Reported adjusted EBITDA came in at $18.2 million, weighed down by $9 million in strategic growth investments, while baseline adjusted EBITDA held at $27.2 million.
- Full-year FY2026 revenue guidance was lowered to a $893 million to $900 million range, with reported adjusted EBITDA trimmed to $100 million to $103 million.
- +8 more takeaways
Velocity Financial Q2 2026 Earnings Call - Portfolio Surges Past $7 Billion as Credit Tightens and Origination Volumes Accelerate
Velocity Financial’s second quarter of 2026 reads like a playbook for disciplined growth. The portfolio crossed $7 billion in unpaid principal balance, driven by steady demand across commercial and re...
- Total loan portfolio reached $7 billion in unpaid principal balance, marking a 19 percent year-over-year increase.
- Second quarter production hit $672.6 million, with unit volume up 3.3 percent year over year despite a slight dollar decline driven by smaller average loan sizes.
- Portfolio net interest margin came in at 3.66 percent, comfortably above the company’s 3.5 percent target.
- +9 more takeaways
"Sunrun" Q2 2026 Earnings Call - Direct Sales Pivot Trims 2026 Guidance While Storage and Grid Monetization Build the Next Growth Engine
Sunrun is deliberately compressing its 2026 volume to force a structural shift toward a direct sales model that promises higher margins, better asset quality, and tighter customer control. The tradeof...
- Sunrun is engineering a deliberate volume contraction to force a pivot to direct sales, cutting affiliate channel volume over 60 percent year-over-year while pushing direct to exceed 85 percent of total origination.
- Storage attachment hit a record 74 percent in Q2, driving over 15,500 battery installations and cementing 4.6 gigawatt hours of residential capacity as the nation’s largest distributed power fleet.
- Full-year guidance was trimmed across the board, with cash generation lowered to $200 million–$375 million and subscriber value cut to $4.6 billion–$4.9 billion, reflecting a slower direct ramp, collapsed affiliate volume, and higher capital costs.
- +7 more takeaways
Traeger Q2 2026 Earnings Call - Revenue Lowered, EBITDA Held Firm as Company Pivots to Accessible Pricing and Lowe's Expansion
Traeger delivered a mixed second quarter, with revenue contracting 17% to $120 million as lower average selling prices and persistent softness in the MEATER business weighed on top-line results. The c...
- Q2 revenue fell 17% to $120 million, driven by a 17% drop in grill sales and a 26% decline in accessories as MEATER promotional performance lagged expectations.
- Full-year 2026 revenue guidance was lowered to $435 million to $465 million, reflecting greater near-term channel friction and a wider range to account for timing variability.
- Adjusted EBITDA guidance remains intact at $57 million to $67 million, with Q2 results coming in at $17 million, up from $14 million a year ago.
- +7 more takeaways
"PacBio" Q2 2026 Earnings Call - SPRQ-Nx Adoption and Clinical Validation Outpace Near-Term Margin Pressures and Guidance Cut
PacBio’s second quarter of 2026 tells a story of technology winning the argument but economics demanding patience. CEO Mark Van Oene takes the helm as Christian Henry steps aside, inheriting a company...
- Leadership transition: Mark Van Oene assumes CEO duties as Christian Henry steps down, remaining on the board as a strategic advisor.
- Q2 revenue flat at $39 million year over year, with consumables growth offsetting a 9 percent decline in instrument sales.
- Full commercial rollout of SPRQ-Nx chemistry reduces cost per 20x HiFi genome to $345 and enables three uses per SMRT cell.
- +9 more takeaways
Evolus Q2 2026 Earnings Call - Raises Full-Year Guidance on Portfolio Momentum and Third Straight Quarter of Positive Adjusted EBITDA
Evolus is no longer pitching a single neurotoxin. The company is systematically building a three-vertical injectable platform, and the second quarter proved the strategy is translating into hard numbe...
- Q2 global net revenue surged 21% year-over-year to $84.1 million, with neurotoxin sales crossing $75.2 million.
- Management raised full-year 2026 revenue guidance to $330 million–$337 million and adjusted gross profit margin to 67.0%–67.5%.
- Adjusted EBITDA turned positive for the third consecutive quarter, reaching $4.7 million in Q2 and improving $12.6 million year-over-year.
- +7 more takeaways